Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis

The Lancet Neurology

Volumn 15, Issue 9, 2016, Pages 925-933

  Whiteley, William N ^a   Emberson, Jonathan ^b   Lees, Kennedy R ^c   Blackwell, Lisa ^b   Albers, Gregory ^d   Bluhmki, Erich ^e   Brott, Thomas ^f   Cohen, Geoff ^a   Davis, Stephen ^g   Donnan, Geoffrey ^h   Grotta, James ⁱ   Howard, George ^j   Kaste, Markku ^k,l   Koga, Masatoshi ^m   von Kummer, Rüdiger ⁿ   Lansberg, Maarten G ^d   Lindley, Richard I ^o   Lyden, Patrick ^p   Olivot, Jean Marc ^q   Parsons, Mark ^r   Toni, Danilo ^s   Toyoda, Kazunori ^m   Wahlgren, Nils ^t   Wardlaw, Joanna ^a   del Zoppo, Gregory J ^u   Sandercock, Peter ^a   Hacke, Werner ^v   Baigent, Colin ^b   more..

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d STANFORD UNIVERSITY   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

ⁱ MEMORIAL HERMANN HOSPITAL   (United States)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k UNIVERSITY OF HELSINKI   (Finland)

^l HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^m NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

ⁿ DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^o UNIVERSITY OF SYDNEY   (Australia)

^p CEDARS SINAI MEDICAL CENTER   (United States)

^q TOULOUSE UNIVERSITY HOSPITAL   (France)

^r UNIVERSITY OF NEWCASTLE   (Australia)

^s SAPIENZA UNIVERSITY OF ROME   (Italy)

^t KAROLINSKA INSTITUTE   (Sweden)

^u UNIVERSITY OF WASHINGTON   (United States)

^v UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADVERSE OUTCOME; AGE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; DISEASE SEVERITY; FUNCTIONAL DISEASE; HUMAN; META ANALYSIS; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; THERAPY DELAY; TIME TO TREATMENT; ADULT; AGED; CEREBRAL HEMORRHAGE; CHEMICALLY INDUCED; COMPLICATION; FACTUAL DATABASE; FEMALE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; STROKE; TIME FACTOR; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; DATABASES, FACTUAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84992202551     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30076-X     Document Type: Article

References (39)

1. 1 Emberson, J, Lees, KR, Lyden, P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384 (2014), 1929–1935.
2. 2 Shinton, R, Questions about authorisation of alteplase for ischaemic stroke. Lancet 384 (2014), 659–660.
3. 3 Alper, BS, Malone-Moses, M, McLellan, JS, Prasad, K, Manheimer, E, Thrombolysis in acute ischaemic stroke: time for a rethink?. BMJ, 350, 2015, h1075.
4. 4 Medicines and Healthcare products Regulatory Agency. Alteplase for treatment of acute ischaemic stroke: independent review. https://www.gov.uk/government/publications/alteplase-for-treatment-of-acute-ischaemic-stroke-independent-review, 2015 (accessed July 24, 2015).
5. 5 The Stroke Thrombolysis Trialists' Collaborative Group. Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis. Int J Stroke 8 (2013), 278–283.
6. 6 Wardlaw, JM, Murray, V, Berge, E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379 (2013), 2364–2372.
7. 7 Wahlgren, N, Ahmed, N, Davalos, A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007), 275–282.
8. 8 Hacke, W, Kaste, M, Fieschi, C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 274 (1995), 1017–1025.
9. 9 IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379 (2012), 2352–2363.
10. 10 Davis, SM, Donnan, GA, Parsons, MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 7 (2008), 299–309.
11. 11 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995), 1581–1588.
12. 12 Hacke, W, Kaste, M, Fieschi, C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 352 (1998), 1245–1251.
13. 13 Hacke, W, Kaste, M, Bluhmki, E, et al. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 359 (2008), 1317–1329.
14. 14 Albers, GW, Clark, WM, Madden, KP, Hamilton, SA, ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. Stroke 33 (2002), 493–495.
15. 15 Clark, WM, Wissman, S, Albers, GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. JAMA 282 (1999), 2019–2026.
16. 16 Haley, EC, Brott, TG, Sheppard, GL, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. Stroke 24 (1993), 1000–1004.
17. 17 Mori, E, Yoneda, Y, Tabuchi, M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42 (1992), 976–982.
18. 18 Wang, S, Wang, X, Zeng, H, et al. Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction. Chinese Crit Care Med 15 (2003), 542–545.
19. 19 Yamaguchi, T, Hayakawa, T, Kiuchi, H, Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 3 (1993), 269–272.
20. 20 Hemmen, TM, Raman, R, Guluma, KZ, et al. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. Stroke 41 (2010), 2265–2270.
21. 21 Whiteley, WN, Slot, KB, Fernandes, P, et al. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 43 (2012), 2904–2909.
22. 22 European Carotid Surgery Trialists' Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 351 (1998), 1379–1387.
23. 23 North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325 (1991), 445–453.
24. 24 Gadhia, J, Starkman, S, Ovbiagele, B, Ali, L, Liebeskind, D, Saver, JL, Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis. Stroke 41 (2010), 300–306.
25. 25 Flynn, D, Nesbitt, DJ, Ford, GA, et al. Development of a computerised decision aid for thrombolysis in acute stroke care. BMC Med Inform Decis Mak, 15, 2015, 6.
26. 26 Kent, DM, Ruthazer, R, Decker, C, et al. Development and validation of a simplified stroke-thrombolytic predictive instrument. Neurology 85 (2015), 942–949.
27. 27 Decker, C, Chhatriwalla, E, Gialde, E, et al. Patient-centered decision support in acute ischemic stroke: qualitative study of patients' and providers' perspectives. Circ Cardiovasc Qual Outcomes 8 (2015), S109–S116.
28. 28 Jovin, TG, Chamorro, A, Cobo, E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 372 (2015), 2296–2306.
29. 29 Campbell, BCV, Mitchell, PJ, Kleinig, TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 372 (2015), 1009–1018.
30. 30 Berkhemer, OA, Fransen, PSS, Beumer, D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 372 (2014), 1009–1018.
31. 31 Goyal, M, Demchuk, AM, Menon, BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 372 (2015), 2285–2295.
32. 32 Saver, JL, Goyal, M, Bonafe, A, et al. Stent-Retriever Thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 372 (2015), 2285–2295.
33. 33 Huang, X, Cheripelli, BK, Lloyd, SM, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol 14 (2015), 368–376.
34. 34 Parsons, M, Spratt, N, Bivard, A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 366 (2012), 1099–1107.
35. 35 Anderson, CS, Robinson, T, Lindley, R, et al. Low dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med, 2016, 10.1056/NEJMoa1515510 published online May 10.
36. 36 IST-3 collaborative group. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial. Lancet Neurol 14 (2015), 485–496.
37. 37 Bentley, P, Ganesalingam, J, Carlton Jones, AL, et al. Prediction of stroke thrombolysis outcome using CT brain machine learning. Neuroimage Clin 4 (2014), 635–640.
38. 38 Brookes, ST, Whitley, E, Peters, TJ, Mulheran, PA, Egger, M, Davey Smith, G, Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 5 (2001), 1–56.
39. 39 von Kummer, R, Broderick, JP, Campbell, BCV, et al. The Heidelberg bleeding classification. Stroke 46 (2015), 2981–2986.